Amyotrophic lateral sclerosis

@article{Hardiman2017AmyotrophicLS,
  title={Amyotrophic lateral sclerosis},
  author={Orla Hardiman and Ammar Al-Chalabi and Adriano Chi{\`o} and Emma M. Corr and Giancarlo Logroscino and Wim Robberecht and Pamela J. Shaw and Zachary Simmons and Leonard H. Berg},
  journal={Nature Reviews Disease Primers},
  year={2017},
  volume={3}
}
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood… Expand
Clinical Manifestation and Management of Amyotrophic Lateral Sclerosis
  • Ashok Verma
  • Medicine
  • Amyotrophic Lateral Sclerosis
  • 2021
TLDR
This chapter summarizes the clinical features and management of ALS and identifies several clinical subtypes of ALS depending on the degree of upper and lower motor neuron involvement. Expand
Disease-modifying therapies in amyotrophic lateral sclerosis
TLDR
The pathological mechanisms relevant to ALS and current and future pharmacological and non-pharmacological trials, including gene and stem cells therapies, will be presented. Expand
Therapeutic news in ALS.
TLDR
This review presents the various treatment options currently being developed for ALS, from old drugs tested in a new indication to innovative drugs obtained via biotechnology or gene therapy, with an emphasis on the range of therapeutic approaches being explored. Expand
Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder
TLDR
This review aims at identifying the most common psychiatric alterations related to ALS and its prognosis, looking at a common genetic background and shared structural brain pathology. Expand
Destination Amyotrophic Lateral Sclerosis
TLDR
A philosophical understanding of how early leads are crucial to understanding the endpoints in ALS is provided, because invariably, all early symptomatic leads are underpinned by neurodegeneration at the cellular, molecular and genomic levels. Expand
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy
TLDR
The recent literature on protein kinase inhibitors currently in pharmaceutical development for this disease as future therapy for AS together with their involvement in the pathobiology of ALS are examined. Expand
Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS).
TLDR
Despite variability, early NMJ dysfunction seems to be a common factor in models with SOD1, TARDBP and FUS mutations, while C9ORF72 models do not appear to follow the same pattern of pathology. Expand
Altered sensory-motor plasticity in amyotrophic lateral sclerosis and complex regional pain type I syndrome: a shared mechanism?
TLDR
This work presents the clinical case of a patient affected by spinal-onset ALS, who developed a type I CRPS (CRPS-I) at the upper limbs. Expand
Molecular and Cellular Mechanisms Affected in ALS
TLDR
A cohesive understanding of the molecular functions of ALS-associated genes may provide clues to common molecular mechanisms across both familial (inherited) and sporadic cases and could be key to the development of effective therapeutic approaches. Expand
Cortical Circuit Dysfunction as a Potential Driver of Amyotrophic Lateral Sclerosis
TLDR
The possibility that initial cortical circuit dysfunction might act as the main driver of ALS onset and progression is discussed and the potential cellular and molecular origins of cortical hyperexcitability in ALS is evaluated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 257 REFERENCES
Hereditary motor neuropathies and motor neuron diseases: which is which
  • C. Hanemann, A. Ludolph
  • Medicine
  • Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2002
TLDR
A comprehensive review of recent work showing that there is a considerable overlap between CMT, MN, SMA, ALS and PLS should help improve understanding of the pathogenesis of motor neuron degeneration and may aid the research for urgently needed new treatment strategies. Expand
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
TLDR
Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS. Expand
Gene discovery in amyotrophic lateral sclerosis: implications for clinical management
TLDR
It is observed that many gene variants associated with ALS have effect sizes between those of mutations that greatly increase risk and those of common variants that have a small effect on risk, and this observation is combined with insights from next-generation sequencing to explore the implications for genetic counselling. Expand
Amyotrophic lateral sclerosis: moving towards a new classification system
TLDR
A new strategy is needed to combine the benefits of a systematic approach to classification with the rich and varied phenotypic descriptions used in clinical practice to avoid confusion between diagnosis and phenotype. Expand
Energy metabolism in amyotrophic lateral sclerosis
TLDR
Results from animal models of ALS have clinical consequences for the management of defective energy metabolism in patients with ALS and pave the way for future therapeutic interventions. Expand
A mutation in sigma‐1 receptor causes juvenile amyotrophic lateral sclerosis
TLDR
A consanguineous family segregating juvenile ALS in an autosomal recessive pattern is described and the genetic variant responsible for the disorder is described. Expand
State of play in amyotrophic lateral sclerosis genetics
TLDR
Current literature of the major genes underlying ALS, SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72 and PFN1 are summarized and how each new genetic discovery is broadening the phenotype associated with the clinical entity the authors know as ALS is outlined. Expand
Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.
TLDR
The findings suggest that a patient presenting with spasticity who does not develop wasting within 3 years most likely has PLS, and which clinical features at onset and during follow-up could help differentiate between PLS and ALS. Expand
Mutations of optineurin in amyotrophic lateral sclerosis
TLDR
It is shown that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS and these findings strongly suggest that OPTN is involved in the pathogenesis of ALS. Expand
Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia
TLDR
Findings link abnormalities in ubiquilin 2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention. Expand
...
1
2
3
4
5
...